# FDA Accepts Sandoz Abbreviated New Drug Applications for Generic Tirzepatide (Mounjaro / Zepbound)

> fda · REPORTED · 2026-06-29

On June 29, 2026, the FDA accepted two Abbreviated New Drug Applications from Sandoz for generic versions of Eli Lilly's tirzepatide, used to treat type 2 diabetes and obesity. If approved, Sandoz believes it could launch one of the first generic tirzepatide products in the US.

- Company: Sandoz
- Sector: therapeutics
- Primary source: https://www.fiercepharma.com/pharma/fierce-pharma-regulatory-tracker-2026

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.